Immunotherapy in the form of immune checkpoint inhibition (ICI) was considered as an alternative and complementary cancer treatment option for TNBC due to its high genomic instability, infiltration of tumor-infiltrating lymphocytes (TILs) and elevated expression of programmed cell death protein ligand 1 (PD-L1) (6–8). The gene discussed is CD274; the disease is cancer.